Shankar Gopi purchased $14K of LRMR

Shankar Gopi (Chief Development Officer) purchased 5,000 shares of Larimar Therapeutics, Inc. (LRMR) at $2.71 on 2026-11-11.

Original reporting
SEC EDGAR · Shankar Gopi
Published Nov 12, 2026, 10:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 10:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LRMR
Neutral
high confidence
Mentioned
$LRMR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRMRNeutralLow
01

Why it matters

The filing adds a modest data point to LRMR's insider activity record but does not materially alter valuation or sentiment.

02

Market read

Insider purchase is a low‑impact event; traders may note it but it is unlikely to drive price movement.

03

What to watch

No disclosed 10b5-1 plan; the insider may have been compelled to buy for personal reasons unrelated to company outlook.

Relevance 4/10Novelty 4/10Timing: after-market filing today

Background

Form 4 disclosures provide transparent insight into insider trading activity. Small purchases by executives are common and often have limited market impact.

Company-level read

Ticker impact

$LRMRNeutralHigh confidence
Context

Chief Development Officer Shankar Gopi bought 5,000 shares of Larimar Therapeutics at $2.7098 each, increasing his stake to 81,443 shares.

Expected impact

minimal upward pressure as the market may view the buy as a positive signal, but impact is limited by the low dollar amount.

Evidence & confidence

Form 4 filing is a primary source; however, the $13.5K purchase is trivial for a public company, so any price effect is expected to be negligible.

Market effects

None

None

None

Counterpoint

The purchase may be routine compensation or portfolio rebalancing, not a strong endorsement of the company's prospects.

Key entities

  • Larimar Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

  • Shankar Gopi

    Chief Development Officer of Larimar Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LRMRMed

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update • Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause o

$LRMRMed

Larimar Therapeutics, Inc. (LRMR): Results of Operations and Financial Condition

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the under

$LRMRMed

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinica

$LRMRMed

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.